ProPhase Labs, Inc. (PRPH)

Market Cap	98.17M
Revenue (ttm)	44.38M
Net Income (ttm)	-16.78M
Shares Out	18.05M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	10.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,176,743
Open	6.32
Previous Close	6.27
Day's Range	5.33 - 6.32
52-Week Range	4.05 - 9.94
Beta	-0.27
Analysts	Strong Buy
Price Target	11.00 (+102.21%)
Earnings Date	May 9, 2024

About PRPH

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, in...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jan 16, 1997
• Employees: 113
• Stock Exchange: NASDAQ
• Ticker Symbol: PRPH

Analyst Forecast

According to one analyst, the rating for PRPH stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(102.21% upside)

Analyst Consensus: Strong Buy